# Skye Bioscience

Type: Company (SKYE)

Source: GetYourBrief — https://getyourbrief.com/entity/skye-bioscience
Canonical HTML page: https://getyourbrief.com/entity/skye-bioscience

## Timeline

- **2026-03-10**: Expected Earnings Call — Management is expected to discuss financial results and 2026 guidance with analysts.
- **2026-03-09**: Earnings Preview Released — Seeking Alpha publishes earnings previews for Evolv Technologies and Skye Bioscience.
- **2025-12-31**: Q4 Fiscal Period Ends — Evolv Technologies concludes its fourth quarter of the 2025 fiscal year.

## Recent coverage (3 stories, network-wide)

### Evolv Technologies Q4 2025 Preview: AI Security Growth Under Scrutiny
2026-03-09 22:03:06 · Sector: saas · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Evolv Technologies is set to report its fourth-quarter 2025 results, with investors focusing on the company's subscription-based revenue growth and AI-driven screening adoption. The report comes amid a broader push for modernized physical security infrastructure across schools, stadiums, and public venues.
Full story: https://getsaasbrief.com/story/evolv-technologies-q4-2025-earnings-preview

### Skye Bioscience Q4 Preview: Obesity Pipeline and Nimacimab Catalysts in Focus
2026-03-09 22:00:31 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Skye Bioscience is set to report Q4 2025 results as the market eyes progress on its Phase 2 nimacimab trial for obesity. The company's pivot toward the metabolic space positions it as a key player in the next-gen CB1 inhibitor race.
Full story: https://getbiobrief.com/story/skye-bioscience-q4-2025-earnings-preview-obesity-market

### Evolv and Skye Bioscience Q4 Earnings: AI Security and Obesity Tech in Focus
2026-03-09 21:59:59 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Evolv Technologies and Skye Bioscience are set to report Q4 2025 results, highlighting two critical growth vectors in the healthcare ecosystem: AI-driven physical security and metabolic clinical innovation. While Evolv faces a pivotal moment in hospital infrastructure adoption, Skye’s update will be scrutinized for progress in the competitive obesity therapeutics market.
Full story: https://gethealthbrief.com/story/evolv-skye-q4-2025-earnings-preview-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.